Syvazul BTV Európska únia - slovenčina - EMA (European Medicines Agency)

syvazul btv

laboratorios syva, s.a.u. - inaktivované vírus katarálnej horúčky oviec, sérotyp 1, kmeň alg2006/01 e1, inaktivované vírus katarálnej horúčky oviec, sérotyp 4, kmeň btv-4/spa-1/2004, inaktivované vírus katarálnej horúčky oviec, sérotyp 8, kmeň bel2006/01 - inaktivované vírusové vakcíny - cattle; sheep - pre aktívnej imunizácie oviec, aby sa zabránilo virému a zníženie klinických príznakov a lézie spôsobené sérotypom sérotypy 1 a/alebo 8 a/alebo znížiť virému* a klinické príznaky a lézie spôsobené sérotypom sérotyp 4for aktívnej imunizácie dobytka, aby sa zabránilo virému spôsobené sérotypom sérotypy 1 a/alebo 8 a/alebo znížiť virému* spôsobené sérotypom sérotyp 4.

Implantát otologický Gyrus ENT Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

implantát otologický gyrus ent

gyrus acmi inc. (olympus) 136 turnpike road southborough, ma spojené štáty americké -

Sutent Európska únia - slovenčina - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Sunitinib Accord Európska únia - slovenčina - EMA (European Medicines Agency)

sunitinib accord

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Qinlock Európska únia - slovenčina - EMA (European Medicines Agency)

qinlock

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinálne stromálne nádory - antineoplastické činidlá - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.